Assessing and Overcoming Resistance Phenomena against a Genetically Modified Vaccinia Virus in Selected Cancer Cell Lines
Autor: | Berchtold, Susanne, Beil, Julia, Raff, Christian, Smirnow, Irina, Schell, Martina, D’Alvise, Janina, Gross, Silvia, Lauer, Ulrich M. |
---|---|
Rok vydání: | 2020 |
Předmět: |
virotherapy resistance
viruses Flucytosine Antineoplastic Agents Vaccinia virus Article Cytosine Deaminase lcsh:Chemistry Viral Proteins super cytosine deaminase prodrug system Cell Line Tumor Humans NCI-60 tumor cell panel Prodrugs 5-fluorocytosine lcsh:QH301-705.5 Oncolytic Virotherapy Cell Death chemovirotherapy Combined Modality Therapy Oncolytic Viruses lcsh:Biology (General) lcsh:QD1-999 Drug Resistance Neoplasm Fluorouracil Genetic Engineering |
Zdroj: | International Journal of Molecular Sciences International Journal of Molecular Sciences, Vol 21, Iss 7618, p 7618 (2020) Volume 21 Issue 20 |
ISSN: | 1422-0067 |
Popis: | Genetically modified vaccinia viruses (VACVs) have been shown to possess profound oncolytic capabilities. However, tumor cell resistance to VACVs may endanger broad clinical success. Using cell mass assays, viral replication studies, and fluorescence microscopy, we investigated primary resistance phenomena of cell lines of the NCI-60 tumor cell panel to GLV-1h94, a derivative of the Lister strain of VACV, which encodes the enzyme super cytosine deaminase (SCD) that converts the prodrug 5-fluorocytosine (5-FC) into the chemotherapeutic compound 5-fluorouracil (5-FU). After treatment with GLV-1h94 alone, only half of the cell lines were defined as highly susceptible to GLV-1h94-induced oncolysis. When adding 5-FC, 85% of the cell lines became highly susceptible to combinatorial treatment none of the tested tumor cell lines exhibited a &ldquo high-grade resistance&rdquo pattern. Detailed investigation of the SCD prodrug system suggested that the cytotoxic effect of converted 5-FU is directed either against the cells or against the virus particles, depending on the balance between cell line-specific susceptibility to GLV-1h94-induced oncolysis and 5-FU sensitivity. The data provided by this work underline that cellular resistance against VACV-based virotherapy can be overcome by virus-encoded prodrug systems. Phase I/II clinical trials are recommended to further elucidate the enormous potential of this combination therapy. |
Databáze: | OpenAIRE |
Externí odkaz: | |
Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |